文章：

溶瘤病毒与肿瘤之战的最新进展

Recent progress in the battle between oncolytic viruses and tumours

原文发布日期：2005-11-18

DOI: 10.1038/nrc1750

类型: Review Article

开放获取: 否

要点：

1. Clinical trials have indicated that oncolytic viruses might be developed as safe and effective anticancer agents.
2. The translation of oncolytic viruses from the culture dish to preclinical tumour models to studies involving patients has revealed new hurdles to cancer therapy that can be overcome using multidisciplinary approaches.
3. Novel strategies can be used to facilitate viral evasion of the immune system, the prevention of viral uptake by the liver, and an increased specificity for tumour cells, either at the cell surface or through intracellular restriction.
4. Oncolytic viruses can be engineered to target the same genetic mutations that provide tumour cells with a proliferative or survival advantage in patients.
5. The intravenous delivery of viruses must be perfected if oncolytic virus-based therapeutics are to be used to treat patients with metastatic tumours.

要点翻译：

1. 临床试验表明，溶瘤病毒有望被开发为安全有效的抗癌制剂。
2. 将溶瘤病毒从培养皿转化至临床前肿瘤模型再至患者研究的过程，揭示了癌症治疗面临的新挑战，这些挑战可通过多学科方法加以克服。
3. 可采用新型策略促进病毒逃逸免疫系统、防止肝脏对病毒的摄取，并通过细胞表面或细胞内限制机制提高对肿瘤细胞的特异性。
4. 可对溶瘤病毒进行基因改造，使其靶向那些赋予肿瘤细胞增殖或生存优势的基因突变。
5. 若要将基于溶瘤病毒的疗法用于治疗转移性肿瘤患者，必须完善病毒的静脉递送技术。

英文摘要：

In the past 5 years, the field of oncolytic virus research has matured significantly and is moving past the stage of being a laboratory novelty into a new era of preclinical and clinical trials. What have recent anticancer trials of oncolytic viruses taught us about this exciting new line of therapeutics?

摘要翻译： 

在过去5年中，溶瘤病毒研究领域已显著成熟，正从实验室新奇阶段迈向临床前和临床试验的新时代。近期溶瘤病毒抗癌试验对这一令人兴奋的新疗法有何启示？

原文链接：

Recent progress in the battle between oncolytic viruses and tumours